5245582026-01-012026-03-315245582026-03-315245582025-03-315245582025-04-012026-03-315245582026-01-012026-03-31in-capmkt:OtherExpenses1Member5245582026-01-012026-03-31in-capmkt:OtherExpenses2Member5245582025-04-012026-03-31in-capmkt:OtherExpenses1Member5245582025-04-012026-03-31in-capmkt:OtherExpenses2Member5245582026-03-31OtherNoncurrentFinancialAssetsDomain15245582026-03-31OtherNoncurrentAssetsDomain15245582026-03-31OtherNoncurrentAssetsDomain25245582026-03-31OtherNoncurrentAssetsDomain35245582026-03-31OtherNoncurrentAssetsDomain45245582026-03-31OtherCurrentFinancialAssetsDomain15245582026-03-31OtherCurrentFinancialAssetsDomain25245582026-03-31OtherCurrentAssetsDomain15245582026-03-31OtherCurrentAssetsDomain25245582026-03-31OtherCurrentAssetsDomain35245582026-03-31OtherCurrentAssetsDomain45245582026-03-31OtherCurrentAssetsDomain55245582026-03-31OtherNoncurrentFinancialLiabilitiesDomain15245582026-03-31OtherCurrentFinancialLiabilitiesDomain15245582026-03-31OtherCurrentFinancialLiabilitiesDomain25245582026-03-31OtherCurrentFinancialLiabilitiesDomain35245582026-03-31OtherCurrentFinancialLiabilitiesDomain45245582026-03-31OtherCurrentFinancialLiabilitiesDomain55245582026-03-31OtherCurrentFinancialLiabilitiesDomain65245582026-03-31OtherCurrentFinancialLiabilitiesDomain75245582026-03-31OtherCurrentLiabilitiesDomain15245582026-03-31OtherCurrentLiabilitiesDomain25245582026-03-31OtherCurrentLiabilitiesDomain35245582026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25245582025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25245582026-01-012026-03-31RelatedPartyTransactionDomain15245582025-12-31RelatedPartyTransactionDomain15245582026-03-31RelatedPartyTransactionDomain15245582026-01-012026-03-31RelatedPartyTransactionDomain25245582025-12-31RelatedPartyTransactionDomain25245582026-03-31RelatedPartyTransactionDomain25245582026-01-012026-03-31RelatedPartyTransactionDomain35245582025-12-31RelatedPartyTransactionDomain35245582026-03-31RelatedPartyTransactionDomain35245582026-01-012026-03-31RelatedPartyTransactionDomain45245582025-12-31RelatedPartyTransactionDomain45245582026-03-31RelatedPartyTransactionDomain45245582026-01-012026-03-31RelatedPartyTransactionDomain55245582025-12-31RelatedPartyTransactionDomain55245582026-03-31RelatedPartyTransactionDomain55245582026-01-012026-03-31RelatedPartyTransactionDomain65245582025-12-31RelatedPartyTransactionDomain65245582026-03-31RelatedPartyTransactionDomain65245582026-01-012026-03-31RelatedPartyTransactionDomain75245582025-12-31RelatedPartyTransactionDomain75245582026-03-31RelatedPartyTransactionDomain75245582026-01-012026-03-31RelatedPartyTransactionDomain85245582025-12-31RelatedPartyTransactionDomain85245582026-03-31RelatedPartyTransactionDomain85245582026-01-012026-03-31RelatedPartyTransactionDomain95245582025-12-31RelatedPartyTransactionDomain95245582026-03-31RelatedPartyTransactionDomain95245582026-01-012026-03-31RelatedPartyTransactionDomain105245582025-12-31RelatedPartyTransactionDomain105245582026-03-31RelatedPartyTransactionDomain105245582026-01-012026-03-31RelatedPartyTransactionDomain115245582025-12-31RelatedPartyTransactionDomain115245582026-03-31RelatedPartyTransactionDomain115245582026-01-012026-03-31RelatedPartyTransactionDomain125245582025-12-31RelatedPartyTransactionDomain125245582026-03-31RelatedPartyTransactionDomain125245582026-01-012026-03-31RelatedPartyTransactionDomain135245582025-12-31RelatedPartyTransactionDomain135245582026-03-31RelatedPartyTransactionDomain135245582026-01-012026-03-31RelatedPartyTransactionDomain145245582025-12-31RelatedPartyTransactionDomain145245582026-03-31RelatedPartyTransactionDomain145245582026-01-012026-03-31RelatedPartyTransactionDomain155245582025-12-31RelatedPartyTransactionDomain155245582026-03-31RelatedPartyTransactionDomain155245582026-01-012026-03-31RelatedPartyTransactionDomain165245582025-12-31RelatedPartyTransactionDomain165245582026-03-31RelatedPartyTransactionDomain165245582026-01-012026-03-31RelatedPartyTransactionDomain175245582025-12-31RelatedPartyTransactionDomain175245582026-03-31RelatedPartyTransactionDomain175245582026-01-012026-03-31RelatedPartyTransactionDomain185245582025-12-31RelatedPartyTransactionDomain185245582026-03-31RelatedPartyTransactionDomain185245582026-01-012026-03-31RelatedPartyTransactionDomain195245582025-12-31RelatedPartyTransactionDomain195245582026-03-31RelatedPartyTransactionDomain195245582026-01-012026-03-31RelatedPartyTransactionDomain205245582025-12-31RelatedPartyTransactionDomain205245582026-03-31RelatedPartyTransactionDomain205245582026-01-012026-03-31RelatedPartyTransactionDomain215245582025-12-31RelatedPartyTransactionDomain215245582026-03-31RelatedPartyTransactionDomain215245582026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524558NEULANDLABNOTLISTEDINE794A01010NEULAND LABORATORIES LIMITEDMain BoardEquity2025-04-012026-03-312026-05-122026-04-20INRLakhsQuarterlyFourth quarterSingle segmentManufacturing of Active Pharmaceuticals2026-05-1214:15:002026-05-1215:45:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-02-10https://www.neulandlabs.com/sites/neulandlabs/files/neuland-labs/Investors/corporate-governance/policies-and-documents/RelatedPartyTransactionPolicy25.pdffalsefalseNot Applicable2026-01-012026-03-31AuditedStandalone77625030001245690007887072000230788700003850210009526590007230900025086700010479000005016643000287042900002870429000767984000-2278600074519800002125231000000021252310008305000213353600012900500010165.65165.6500165.65165.651. The financial results for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 12, 2026.The Statutory Auditors have issued an unmodified audit opinion on the financial results for the year ended March 31, 2026 and have issued an unmodified conclusion in respect of limited review for the quarter ended March 31, 2026. <BR> <BR> 2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <BR> <BR> 3. The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments". In accordance with Ind AS 108 - 'Operating segments', segment information has been given in the audited consolidated financial results of the Company and therefore no separate disclosure on segment information is given in these audited standalone financial results. <BR> <BR> 4. During the previous year, the Company has fully transferred an investment property located in Nanakramguda, Hyderabad, Telangana, through perpetual lease, resulting in total profit of Rs. 7,640.36 lakhs (For the quarter ended June 30, 2024: Rs. 2,062.56 lakhs and for the quarter ended December 31, 2024: Rs. 5,577.80 lakhs) being the profit is exceptional in nature, it has been disclosed as a separate line item. <BR> <BR> 5. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has considered the impact of the changes, consistent with the Labour Codes, draft rules, FAQs and legal opinion. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. <BR> <BR> 6. The EPS for quarters has not been annualised. <BR> <BR> 7. The Board of Directors has recommended a final dividend of Rs. 34 only per equity share of Rs. 10 each subject to approval of shareholders for the year ended March 31, 2026. <BR> <BR> 8. The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and published unaudited figures upto nine months of the relevant financial year.2025-04-012026-03-31AuditedStandalone202298540003016390002053149300081976450000-64262300032882040002394540009173050003654177000156541620004877331000048773310001288835000-4255400012462810000363105000000003631050000351600036345660001290050001018521119000283.01283.0100283.01283.01Manufacturing expense517222000Other Expenses530678000Manufacturing expense1916144000Other Expenses1738033000892269200020949900000279461000051812000108460000021404000001177920001391960000455554000144697000005102864000054135310007530810002782945000043381000899293800007178760001481367800000292833780001290050001852950800018658513000186585130001609473000000996948000260642100015177300067423500003432429000356658000126429000266018100027866100001313878000445714600025309400002307800018127200007192436000001062486500029283378000Security Deposits117792000Prepaid expenses1479000Capital Advances412111000Balances with government authorities2337000Income Tax Assets (Net)39627000Interest accrued on bank deposits31653000Unbilled revenues11728000Prepaid expenses136575000Advance to suppliers114499000Balances with government authorities392570000Export benefits receivable74038000Other advances194000Lease Liability996948000Interest accrued but not due on borrowings588000Interest accrued on micro enterprises and small enterprises payable587000Unclaimed dividends2328000Capital creditors310948000Employee benefits payable387526000Accrual for expenses562258000Lease Liability49643000Advances from customers2445005000Liability towards Corporate Social Responsibility ('CSR') expenditure1383000Statutory liabilities84552000239454000-1245295000-22421180000-26357000852000-71751000-6745000-3400001696760000173963400009173050000210600085564000200776000013495000010053100000000-432760000-3675510004509780000000103395800003475822000000000009263000390167700000058798000010846000000002652374000150000000000000860510000-1513719000-42373520000000000010560930004471780007477600015395900017040500000209775000-5517550001046000-5507090001303790000753081000Re-measurement gain/(loss) on defined benefit plans6565000Changes in fair value of equity instruments through other comprehensive income453300011098000Re-measurement gain/(loss) on defined benefit plans165000Changes in fair value of equity instruments through other comprehensive income45330004698000279300011820000083050003516000Neuland Laboratories Limited******Dr. Davuluri Rama Mohan Rao******Executive Chairman and KMPRemunerationAs per the Companies Act, 2013 and Shareholders' Approval910840000-86700000Neuland Laboratories Limited******Mr. Davuluri Sucheth Rao******Executive Vice Chairman and KMPRemunerationAs per the Companies Act, 2013 and Shareholders' Approval823840000-78000000Neuland Laboratories Limited******Mr. Davuluri Saharsh Rao******CEO & Managing Director and KMPRemunerationAs per the Companies Act, 2013 and Shareholders' Approval823840000-78000000Neuland Laboratories Limited******Mr.Ravi Shankar Gopinath******Non-Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved37700000-3500000Neuland Laboratories Limited******Prasad Raghava Menon******Non Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved38600000-3500000Neuland Laboratories Limited******Dr Christopher M Cimarusti******Non-Executive Non-Independent DirectorAny other transactionSitting Fee & CommissionApproved3600000-628000-3500000Neuland Laboratories Limited******Sugata Sircar******Non Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved38200000-3500000Neuland Laboratories Limited******Pallavi Bhakru******Non Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved38600000-3500000Neuland Laboratories Limited******Mr Homi Rustam Khusrokhan******Non Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved38400000-3500000Neuland Laboratories Limited******Mr. Abhijit Majumdar******Chief Financial Officer and KMPRemunerationApproved10565000-1937000-3169000Neuland Laboratories Limited******Mrs. Sarada Bhamidipati******Company Secretary & Complinace OfficerRemunerationApproved2600000-293000-442000Neuland Laboratories Limited******Mrs. Davuluri Vijaya Rao******Relative of DirectorAny other transactionLease rentApproved487100000Neuland Laboratories Limited******Mr. Davuluri Sucheth Rao******Executive Vice Chairman and KMPAny other transactionOffice Lease rentApproved599300000Neuland Laboratories Limited******Mr. Davuluri Saharsh Rao******CEO & Managing Director and KMPAny other transactionOffice Lease rentApproved599300000Neuland Laboratories Limited******Mr. Davuluri Sucheth Rao******Executive Vice Chairman and KMPAny other transactionSecurity Deposit givenApproved01214000012140000Neuland Laboratories Limited******Mr. Davuluri Saharsh Rao******CEO & Managing Director and KMPAny other transactionSecurity Deposit givenApproved01214000012140000Neuland Laboratories Limited******Mrs. Davuluri Vijaya Rao******Relative of DirectorAny other transactionSecurity Deposit givenApproved019200001920000Neuland Laboratories Limited******Neuland Laboratories INC******Wholly owned subsidiaryAny other transactionBusiness PromotionApproved94251000-72798000-88222000Neuland Laboratories Limited******Neuland Laboratories KK******Wholly owned subsidiaryAny other transactionBusiness PromotionApproved14526000-6340000-7020000Neuland Laboratories Limited******Neuland Laboratories Limited Employees Group Gratuity Scheme******Post Employment Benefit TrustAny other transactionContribution to Employee Gratuity TrustApproved1800000000Neuland Laboratories Limited******Neuland Foundation******Entities with joint control or significant influence over entityAny other transactionContribution towards CSRApproved1681700000452218000AuditedtrueM S K A & Associates LLP, Chartered Accountantstrue2027-07-31